Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing

Mar 08 2010

• By The Pink Sheet

Related Content

AstraZeneca Takes Out Antibiotic Firm Novexel, With Cash Back from Forest

Dec 23 2009

AstraZeneca Pays $200M Upfront For Global Rights To Targacept's MDD Candidate

Dec 03 2009

Nektar Dips Into AstraZeneca's Deep Pockets With OIC Deal

Sep 21 2009

AZ Continues To Buy Pipeline With $100M Rigel Deal

Feb 16 2010

AstraZeneca Reports Higher Profits, But Cuts R&D Jobs

Jan 28 2010

AstraZeneca To Reclaim Full Rights To Several Drugs From Merck For $647M

Mar 01 2010

AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track

Feb 11 2009

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window